Motivation: Immunotherapy for glioma has demonstrated promising potential in preclinical studies. However, the dynamic assessment of its effectiveness in the brain presents a significant challenge.
Goal(s): To continuously monitor the effectiveness of PD-1 inhibitors when combined with bioengineered Escherichia coli in the treatment of GBM in mouse model, utilizing high-field animal MRI technology.
Approach: Throughout the treatment of glioma-bearing mouse with E. coli and/or PD-1 inhibitors, we employed multimodal MRI and immunofluorescence techniques to routinely observe changes within the tumor microenvironment.
Results: The high-field MRI technology utilized for monitoring the tumor microenvironment revealed positive outcomes for the combination therapy, consistent with our laboratory findings.
Impact: Our research suggests that the fusion of bioengineered Escherichia coli and PD-1 inhibitors may herald a groundbreaking development in GBM immunotherapy, with high-field MRI technology serving as a potent tool for the real-time evaluation of this combination therapy's efficacy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords